Brand-name drug
Trijardy price, strengths & recalls
Brand of empagliflozin / linagliptin / metformin (generic)
Pharmacies pay $338.10 for 30 tablets of Trijardy 10 mg / 5 mg / 1000 mg (24 hr) extended-release tablet this week, and from $168.80 to $338.10 across its 4 priced strengths and forms. Its official label last changed on August 25, 2026.
Brand- Fair cash price
- $399.32
- Strengths
- 4
- Makers
- 1
- Updated
- Nov 11
Trijardy price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 5 mg / 2.5 mg / 1000 mg (24 hr) extended-release tablet Brand | $5.67 | $170.02 / 30 tablets |
| 10 mg / 5 mg / 1000 mg (24 hr) extended-release tablet Brand | $11.27 | $338.10 / 30 tablets |
| 12.5 mg / 2.5 mg / 1000 mg (24 hr) extended-release tablet Brand | $5.63 | $168.80 / 30 tablets |
| 25 mg / 5 mg / 1000 mg (24 hr) extended-release tablet Brand | $11.24 | $337.07 / 30 tablets |
The lowest cost per tablet is 12.5 mg / 2.5 mg / 1000 mg (24 hr) extended-release tablet at $5.63. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Trijardy vs generic empagliflozin / linagliptin / metformin
There is no generic version of Trijardy on the market yet. Its last listed patent or exclusivity runs to December 8, 2037 - generics often follow, though court cases and settlements can move the date either way.
GenericEmpagliflozin / linagliptin / metformin pricesSupply status: shortages & recalls
What people paid for Trijardy
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use TRIJARDY XR safely and effectively. See full prescribing information for TRIJARDY XR. TRIJARDY® XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2020
WARNING: LACTIC ACIDOSIS
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.1)].
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see Dosage and Administration (2.3), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].
If metformin-associated lactic acidosis is suspected, immediately discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].
WARNING: LACTIC ACIDOSIS
See full prescribing information for complete boxed warning.
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1)
Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1)
If lactic acidosis is suspected, discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)
Recent major changes (as listed on the label)
Boxed Warning | 8/2026 |
Warnings and Precautions: | |
Lactic Acidosis (5.1) | 8/2026 |
Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), and Genital Mycotic Infections (5.5) | 10/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA212614 · Boehringer Ingelheim
- First approved
- January 27, 2020 (6 years ago)
- Latest approved change
- August 11, 2026
- Approved label
- PDF, Aug 18, 2026
- Generic makers
- None on the market
- Last patent listed
- December 8, 2037
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Trijardy questions
How much does trijardy cost without insurance?
Pharmacies pay about $338.10 for 30 tablets of trijardy 10 mg / 5 mg / 1000 mg (24 hr) extended-release tablet ($11.27 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $399.32. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Trijardy?
Yes: empagliflozin / linagliptin / metformin. Compare empagliflozin / linagliptin / metformin prices.
Is trijardy in shortage?
No shortage is reported for trijardy right now. We check the national shortage list every day.
Has trijardy been recalled?
No recalls are on record for trijardy.
When did the trijardy label last change?
The official label was last updated on August 25, 2026 (version 11). See what changed.
Talk about trijardy
No comments yet. Questions, tips, what worked for you - start the conversation.